ZURICH (Reuters) -Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets. The company, which develops DARPin protein therapeutics – a new type of engineered protein […]
Health
Molecular Partners to cut workforce by a quarter
Audio By Carbonatix
ZURICH (Reuters) -Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.
The company, which develops DARPin protein therapeutics – a new type of engineered protein drugs – said the cuts aim to extend its cash runway into 2028, beyond earlier guidance of 2027.
CEO Patrick Amstutz said the move will support the advancement of pipeline candidates MP0533 and MP0712, with clinical data expected in the second half of 2025.
(Reporting by John Revill, Editing by Miranda Murray)